Press "Enter" to skip to content

Gottlieb says vaccines could be approved for kids 5-11 by end of October

Washington — Former Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb predicted Sunday that the company he helmed will authorize Pfizer’s coronavirus vaccine for emergency use in kids ages 5 to 11 by the end of October.

In an interview with “Face the Nation,” Gottlieb, who serves on Pfizer’s board of administrators, stated the drug company is anticipating to have information on its vaccines in younger kids earlier than the end of September, which can then be filed with the FDA “very quickly.” The company then has stated it can be weeks, somewhat than months, earlier than figuring out whether or not it can authorize the vaccine for kids ages 5 to 11. 

“In a best-case scenario, given that timeline they’ve just laid out, you could potentially have a vaccine available to children aged 5 to 11 by Halloween,” Gottlieb stated. “If everything goes well, the Pfizer data package is in order, and FDA ultimately makes a positive determination, I have confidence in Pfizer in terms of the data that they’ve collected. But this is really up to the Food and Drug Administration to make an objective determination.”

Pfizer has been conducting scientific trials of its two-dose vaccine in kids 2 years and older, and its approval could be essential to serving to fight the unfold of the extremely contagious Delta variant in colleges. Children signify 25% of new COVID-19 infections.

The shot has already been licensed for kids ages 12 to fifteen, and Gottlieb stated he believes COVID vaccines will ultimately be amongst these required for kids in public colleges.

“I think you’re going to see more local school districts and governors make those recommendations,” he stated. “Eventually ACIP is going to make a recommendation about whether this should be included in the childhood immunization schedule. My guess is they’re waiting for more of the vaccines to be fully licensed to make that kind of a recommendation. But I would expect this eventually to be required as part of the childhood immunization schedule.”

For dad and mom who might be cautious of their kids receiving a vaccine that’s below emergency use, somewhat than totally approved by the FDA for kids, Gottlieb inspired them to seek the advice of with their pediatricians, however pressured they aren’t dealing with a “binary decision” of getting their kids vaccinated in opposition to COVID-19 or not.

“There’s different ways to approach vaccination. You could go with one dose for now. You could potentially wait for the lower dose vaccine to be available, and some pediatricians may make that judgment. If your child’s already had COVID, one dose may be sufficient. You could space the doses out more,” he stated. “So, there’s a lot of discretion that pediatricians can exercise, making largely off-label judgments, but exercising discretion within the context of what an individual child’s needs are, their risk is, and what the parents’ concerns are.”

While the FDA is anticipated to decide on whether or not to authorize COVID vaccines in kids within the coming weeks, federal well being businesses are additionally weighing whether or not to approve booster pictures for vaccinated Americans.

The Biden administration initially introduced in August that it was ready to start providing the boosters the week of September 20, and Americans would wish to get their extra pictures eight months after receiving their second vaccine dose. But Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, advised “Face Nation” final week that it could solely be Pfizer’s booster that receives federal approval by September 20. 

The FDA’s advisory committee is scheduled to satisfy Friday to debate the booster pictures, and Gottlieb stated the company is positioned to behave “very quickly” relying on the result of the meeting. If the boosters are approved, he stated a Centers for Disease Control and Prevention advisory committee would then advocate which populations would get them first, probably those that are at greater danger of extreme sickness or loss of life from COVID-19 corresponding to aged Americans residing in nursing properties.

Pfizer has already filed its application with the FDA for approval of its booster, and Gottlieb predicted Johnson & Johnson will probably be subsequent to take action.

“They have very good data also looking at boosters. They’ve showed a good response,” he stated of Johnson & Johnson. “And I think that vaccine also could be in a position to get authorized by FDA in short order.”